Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Investor Presentation (June 2017)
16 slides from Imagion Biosystems's investor presentation, June 2017
Slide 1: Company Overview
Company Overview June 2017 www.imagionbiosystems.com
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Imagion Biosystems Limited (Imagion) in relation to a proposed sale or issue of shares to certain investors who are sophisticated or professional investors and wholesale clients (as those terms are defined in the Corporations Act 2001 (Cth) (Corporat
Slide 3: MagSense Technology: Revolutionizing Cancer Diagnosis
MagSense™ Technology Revolutionizing Cancer Diagnosis Optimizing Patient Care and Reducing Mortality Rates through the Early Detection of Cancer 3
Slide 4: Investment Highlights
Investment Highlights $100 Billion 8 Patents “Printer & Ink” model Annual global Core Product includes both the instrument and a technology spending on diagnostic consumable covered in cancer diagnosis major markets in imaging and through to $2 Billion Platform pathology 2029 Technology Addressable
Slide 5: The Opportunity in Cancer Diagnostics
The Opportunity in Cancer Diagnostics $100B Global Cancer Diagnostics Market Market Characteristics Source: Transparency Market Research – Global Cancer Diagnostics Market 2014-2020 • Large market growing 7% annually $30,000 $26,044 • Imaging makes up the largest proportion $25,000 • Early detection
Slide 6: Advantages of MagSense Technology
Advantages of MagSense™ Technology Improved Sensitivity Non-invasive • 1000x more sensitive than • A low dose of cancer current imaging methods. specific nanoparticles are administered by simple • Early small tumors (~1mm) intravenous injection. not readily detectable with current medical imaging •
Slide 7: Competitive Position
Competitive Position Reduced Patient Risks Less Expensive • MagSense™ technology uses a significantly • Unlike most imaging methods, the MagSense™ lower magnetic field than MRI, and a routine instrument is relatively inexpensive and does not examination is completed in minutes. require a specialized
Slide 8: MagSense Technology
MagSense™ Technology • All nanoparticles lose their magnetization Tumor Cell (i.e. “relax”) after the low magnetic field is turned off Magnetic field strength Magnet Pulse • A nanoparticle attached to a bio-marked cancer cell will relax more slowly than an |------- Measurement Period------| unattach
Slide 9: Near-term Addressable Markets – US$2 Billion
Near-term Addressable Markets – US$2 Billion Breast Cancer Prostate Cancer Ovarian Cancer • Invasion of the regional • For patients with PSA blood • For patients with persistent lymph nodes is an early biomarker test, only 30% elevated CA-125 blood hallmark of metastatic breast have cancer biomarker
Slide 10: Strategic Relationships
Strategic Relationships Pre-Clinical Collaborations Research collaborations are in place with some of the world’s pre-eminent cancer medical centers to demonstrate in vivo detection of breast, prostate, and ovarian cancer in pre- clinical models. Dr. John Hazle Dr. John Babich Dr. Helen Hathaway Cha
Slide 11: Board and Management
Board and Management Robert Proulx David Ludvigson Michael Harsh John Hazle PhD Jovanka Naumoska Chairman & CEO Non Exec Director Non Exec Director Non Exec Director Director / Secretary CEO Nanomix Founder Terapede Chair Imaging Physics Business Mgr Systems MD Anderson ANSTO • Operationally • Finan
Slide 12: IPO/Capital Structure
IPO/Capital Structure Imagion lists on the Australian Securities Exchange (ASX) on 21 June 2017 • A$12 million raised as part of IPO • IPO funds initial commercial product development & achieve first-in-human clinical study Shares issued to Seed Shareholders 62,183,576 Shares issued to Mason Group 3
Slide 13: Use of Funds and Timeline
Use of Funds and Timeline 4Q16 1H17 2H17 2018 2019 Lead formulation Identified Finalize instrument specs Validate preclinical model(s) Pre-IDE meeting Nanoparticle safety studies Prototype clinical instrument Design of study IDE submission Clinical Study Enrollment First Patient Dose Clinical Study
Slide 14: Milestones and Value Inflection Points
Milestones and Value Inflection Points • Clearance by FDA/TGA for “Investigational Use” Initiate BrCa Clinical Regulatory significantly reduces technical risk – particles and Study – 1st Patient Clearance for instrument are deemed safe for use in clinical setting Dose Commercial Use • 1st Clinical s
Slide 15: Imagion Biosystems Message Map
Imagion Biosystems Message Map Technology Predicate devices like EndoMag have Opportunities to expand beyond cancer and into ~1500 Cancer Centers in the Markets therapeutic applications US for diagnosis and gained clearance treatment FDA “Medical Iron oxide nanoparticles 47 NCI designated Device” op
Slide 16: Contact
Bob Proulx, President & CEO Investor Relations Imagion Biosystems Matt Wright 800 Bradbury SE Suite 213 NWR Communications Albuquerque, NM 87106 matt@nwrcommunications.com.au bob.proulx@imagionbio.com +61-451-896-420 505-243-1058 16
Imagion Biosystems — Investor Presentation (June 2017) on 6ix